BioXcel Therapeutics, Inc.
BTAI
$4.98
-$0.25-4.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -164.50% | 33.20% | 20.45% | -64.48% | 69.02% |
| Total Depreciation and Amortization | -1.32% | -1.30% | 0.00% | 0.00% | -1.28% |
| Total Amortization of Deferred Charges | 12.29% | 57.66% | 109.43% | 10.42% | 123.26% |
| Total Other Non-Cash Items | 202.95% | 51.85% | -387.27% | 83.92% | -305.09% |
| Change in Net Operating Assets | 251.93% | -148.06% | 348.98% | 75.59% | -226.96% |
| Cash from Operations | -4.42% | 18.68% | 9.36% | 29.50% | -30.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.00% | 100.06% | 1,395.94% | -91.45% | -79.52% |
| Repurchase of Common Stock | 100.00% | 97.83% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.63% | -348.60% | -1,178.57% | 91.46% | -40.17% |
| Cash from Financing | -98.96% | 208.75% | 841.85% | -91.44% | -80.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,173.17% | 111.00% | 33.69% | 11.11% | -300.34% |